Croda International (CRDA)

Sector:

Industrial Chemicals

Index:

FTSE 100

4,902.00p
   
  • Change Today:
      49.00p
  • 52 Week High: 7,096.00
  • 52 Week Low: 4,076.00
  • Currency: UK Pounds
  • Shares Issued: 142.54m
  • Volume: 320,578
  • Market Cap: £6,987m
  • RiskGrade: 108

SkinBioTherapeutics strikes deal with chemicals giant Croda

By Josh White

Date: Wednesday 20 Nov 2019

LONDON (ShareCast) - (Sharecast News) - Skin health-focussed life sciences company SkinBioTherapeutics has signed a commercial agreement with speciality chemicals giant Croda International, it announced on Wednesday.
The AIM-traded firm said that under the terms of the agreement, its proprietary 'SkinBiotix' platform would be paired with Croda's expertise in the development and commercialisation of "unique, sustainable" cosmetic ingredients, focusing specifically on the growing skincare actives market.

Sederma, part of Croda, is a specialist in bioactive ingredients for the cosmetic industry, and would be responsible for the development, manufacture and commercialisation of the SkinBiotix technology.

As design-and-build of the active ingredient is carried out, there would be concurrent testing in focussed application areas which would be detailed in further, additional agreements, the company explained.

Any licensed products resulting from the agreement would be sold to Croda's global portfolio of personal care customers.

SkinBioTherapeutics said it would be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership, which would subsequently be agreed on successful development of the technology.

Sales and distribution rights were for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors, the board added.

"The focus of this year has been on commercialisation, therefore, we are delighted that the first announcement has been a significant deal with a world-leading company such as Croda and being able to utilise the expertise within Sederma," said SkinBioTherapeutics chief executive officer Stuart Ashman.

"This partnership brings together our innovation in the microbiome space and Sederma's track record of developing world-class cosmetic ingredients.

"As we have stated before, we intend to build a significant portfolio around our core technology across multiple sectors to create further value for our shareholders - this deal with Croda is just the beginning."

At 1554 GMT, shares in SkinBioTherapeutics were up 0.6% at 16.85p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CRDA Market Data

Currency UK Pounds
Share Price 4,902.00p
Change Today 49.00p
% Change 1.01 %
52 Week High 7,096.00
52 Week Low 4,076.00
Volume 320,578
Shares Issued 142.54m
Market Cap £6,987m
RiskGrade 108

CRDA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.73% below the market average83.73% below the market average83.73% below the market average83.73% below the market average83.73% below the market average
87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average
Price Trend
24.23% below the market average24.23% below the market average24.23% below the market average24.23% below the market average24.23% below the market average
44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average
Income
84.36% below the market average84.36% below the market average84.36% below the market average84.36% below the market average84.36% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
86.68% below the market average86.68% below the market average86.68% below the market average86.68% below the market average86.68% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 9
Sell 0
Strong Sell 1
Total 16
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CRDA Dividends

  Latest Previous
  Final Interim
Ex-Div 18-Apr-24 31-Aug-23
Paid 29-May-24 03-Oct-23
Amount 62.00p 47.00p

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 236,539 @ 4,902.00p
16:35 217 @ 4,902.00p
16:35 288 @ 4,902.00p
16:35 360 @ 4,902.00p
16:35 1,016 @ 4,902.00p

CRDA Key Personnel

Chair Anita Frew
Finance Director Louisa Burdett

Top of Page